Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor‐tezacaftor‐ivacaftor, are primarily eliminated through cytochrome P450 (CYP) 3A–mediated metabolism. This creates a therapeutic challenge to the treatment of coronavirus disease 2019 (COVID‐19) with nirmatrelvir‐ritonavir in people with cystic fibrosis (CF) due to the potential for significant drug–drug interactions (DDIs). However, the population with CF is more at risk of serious illness following COVID‐19 infection and hence it is important to manage the DDI risk and provide treatment options. CYP3A‐mediated DDI of elexacaftor‐tezacaftor‐ivacaftor was evaluated using a physiologically‐based pharmacokinetic modeling approach. Modeling was performed incorporating physiological information and drug‐dependent parameters of elexacaftor‐tezacaftor‐ivacaftor to predict the effect of ritonavir (the CYP3A inhibiting component of the combination) on the pharmacokinetics of elexacaftor‐tezacaftor‐ivacaftor. The elexacaftor‐tezacaftor‐ivacaftor models were verified using independent clinical pharmacokinetic and DDI data of elexacaftor‐tezacaftor‐ivacaftor with a range of CYP3A modulators. When ritonavir was administered on Days 1 through 5, the predicted area under the curve (AUC) ratio of ivacaftor (the most sensitive CYP3A substrate) on Day 6 was 9.31, indicating that its metabolism was strongly inhibited. Based on the predicted DDI, the dose of elexacaftor‐tezacaftor‐ivacaftor should be reduced when coadministered with nirmatrelvir‐ritonavir to elexacaftor 200 mg–tezacaftor 100 mg–ivacaftor 150 mg on Days 1 and 5, with delayed resumption of full‐dose elexacaftor‐tezacaftor‐ivacaftor on Day 9, considering the residual inhibitory effect of ritonavir as a mechanism‐based inhibitor. The simulation predicts a regimen of elexacaftor‐tezacaftor‐ivacaftor administered concomitantly with nirmatrelvir‐ritonavir in people with CF that will likely decrease the impact of the drug interaction.

[1]  B. Quon,et al.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review , 2020, Journal of clinical medicine.

[2]  A. Vermeulen,et al.  Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019 , 2020, Clinical Pharmacokinetics.

[3]  E. Haseltine,et al.  Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor , 2020, Pulmonary Therapy.

[4]  P. Burgel,et al.  Impact of COVID-19 on people with cystic fibrosis , 2020, The Lancet Respiratory Medicine.

[5]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[6]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[7]  Nirav R. Shah,et al.  Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding , 2019, Pharmaceutics.

[8]  V. Garg,et al.  Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor , 2019, Clinical and translational science.

[9]  E. Acosta,et al.  Sensitivity of ivacaftor to drug‐drug interactions with rifampin, a cytochrome P450 3A4 inducer , 2018, Pediatric pulmonology.

[10]  G. Lukács,et al.  Mutation-specific downregulation of CFTR2 variants by gating potentiators , 2017, Human molecular genetics.

[11]  M. Barry,et al.  The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers , 2017, British journal of clinical pharmacology.

[12]  David Y. Thomas,et al.  Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor) , 2016, British journal of pharmacology.

[13]  Vikram Sinha,et al.  Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA , 2016, Clinical Pharmacokinetics.

[14]  A. Courville,et al.  Increase in body mass index from normal weight to overweight in a cross-sectional sample of healthy research volunteers. , 2014, Nutrition research.

[15]  L. Wienkers,et al.  Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4 , 2014, Molecular Pharmacology.

[16]  N. Dokholyan,et al.  Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.

[17]  W. Haefeli,et al.  Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy , 2011, Clinical pharmacology and therapeutics.

[18]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[19]  Ying-Hong Wang,et al.  Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors , 2010, Drug Metabolism and Disposition.

[20]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .

[21]  Kiyomi Ito,et al.  CYP 3 A 4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005 .